Blog

The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a brief screening and severity measurement tool for generalized anxiety disorder. Format: self-administered questionnaire; takes about 2 minutes; can be paper or electronic; each item asks about anxiety symptoms over past 2 weeks. The 7 items: feeling nervous, anxious, or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless it’s hard to sit still; becoming easily annoyed or irritable; feeling afraid as if something awful might happen. Each scored 0 (not at all) to 3 (nearly every day); total 0-21. Score interpretation: 0-4 minimal; 5-9 mild; 10-14 moderate; 15-21 severe. Also useful as preliminary screen for other anxiety disorders (panic disorder, social phobia, PTSD). Validated, freely available, no licensing fee. Often paired with PHQ-9 for combined depression/anxiety screening. Significantly more common than in general population. Statistics: anxiety disorders affect about 20% of adults with diabetes (general population about 12-15%); about 40% of adults with diabetes have elevated anxiety symptoms even if not meeting full disorder criteria. Specific anxiety subtypes: generalized anxiety disorder (persistent worry; about 14% prevalence in diabetes); diabetes-specific distress (worry about diabetes management, complications, future; very common; about 30-45% prevalence); hypoglycemia anxiety (fear of low blood sugar; particularly common in type 1 diabetes and insulin users); needle/blood phobia (interferes with self-care); panic disorder (sometimes confused with hypoglycemia); social anxiety related to diabetes management. Impact: poor glycemic control (anxiety affects self-management); avoidance of self-monitoring; reluctance to take medications appropriately (especially insulin); avoidance of healthcare appointments; worse complications. Bidirectional — diabetes worsens anxiety; anxiety worsens diabetes outcomes. Screening important; treatment effective. Diabetes distress refers to the emotional burden specifically related to living with diabetes — worry about complications, fatigue from constant self-management, frustration with healthcare system, social burden. Different from clinical depression or anxiety disorder. DDS-17 (Diabetes Distress Scale — 17 items) — validated screening tool with subscales: emotional burden, physician-related distress, regimen-related distress, interpersonal distress. Score: each item 1 (no distress) to 6 (serious distress); average score above 3 considered elevated. About 30-45% of adults with diabetes have elevated diabetes distress. Treatment: diabetes-specific cognitive behavioral therapy; diabetes self-management education; peer support groups; addressing specific concerns (complications, costs, regimen burden); not always pharmacologic.

GAD-7 Score Interpretation

The 7 GAD-7 Items (Past 2 Weeks)

Anxiety in Diabetes

• Generalized anxiety disorder — about 14% prevalence in diabetes.
• Diabetes distress — about 30-45% have elevated diabetes-specific worry.
• Hypoglycemia fear — common in insulin users.
• Needle/blood phobia — interferes with self-care.
• Panic disorder — sometimes confused with hypoglycemia.
• Health-related anxiety — about complications.
• Social anxiety related to diabetes (insulin in public, food restrictions).
• About 20% of adults with diabetes have an anxiety disorder.
• Often co-occurs with depression.

Diabetes-Specific Anxiety Issues

• Hypoglycemia anxiety — fear of low blood sugar episodes.
• Hyperglycemia anxiety — fear of long-term damage.
• Complication anxiety — fear of vision loss, amputation, dialysis.
• Death anxiety — fear of dying from diabetes.
• Pump anxiety — fear of equipment failure.
• CGM anxiety — fear of alarms or being constantly monitored.
• Travel anxiety — managing diabetes away from home.
• Food anxiety — constant carb counting; relationships with food.
• Exercise anxiety — fear of hypoglycemia during/after.
• Healthcare anxiety — A1C results, doctor visits.

Treatment Options

• Cognitive behavioral therapy (CBT) — first-line for anxiety.
• Exposure therapy for specific phobias (needles, blood).
• Mindfulness-based stress reduction (MBSR).
• Acceptance and commitment therapy (ACT).
• SSRIs — escitalopram, sertraline — first-line medications.
• SNRIs — duloxetine (also for diabetic neuropathy), venlafaxine.
• Buspirone (Buspar) — anti-anxiety, no addiction risk.
• Avoid long-term benzodiazepines — dependence risk; fall risk in older adults.
• CGM technology may reduce hypoglycemia anxiety.
• Diabetes education reduces uncertainty-driven anxiety.
• Peer support groups (in-person, online).
• Regular exercise — proven anxiolytic.
• Sleep hygiene.
• Limit caffeine and alcohol.

When to See Specialist

• Severe anxiety (GAD-7 score 15+).
• Treatment-resistant anxiety.
• Co-occurring depression with PHQ-9 elevated.
• Suicidal thoughts (immediate evaluation).
• Panic disorder with frequent attacks.
• Specific phobias interfering with diabetes care.
• Substance use as coping mechanism.
• Need for medication management.
• Mental health crisis — 988 Suicide and Crisis Lifeline.

The Bottom Line

The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a brief screening and severity measurement tool for generalized anxiety disorder. Format: self-administered questionnaire; takes about 2 minutes; can be paper or electronic; each item asks about anxiety symptoms over past 2 weeks. The 7 items: feeling nervous, anxious, or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless it’s hard to sit still; becoming easily annoyed or irritable; feeling afraid as if something awful might happen. Each scored 0 (not at all) to 3 (nearly every day); total 0-21. Score interpretation: 0-4 minimal; 5-9 mild; 10-14 moderate; 15-21 severe. Also useful as preliminary screen for other anxiety disorders. Validated, freely available, no licensing fee. Often paired with PHQ-9 for combined depression/anxiety screening. Significantly more common than in general population. Anxiety disorders affect about 20% of adults with diabetes (general population about 12-15%); about 40% of adults with diabetes have elevated anxiety symptoms even if not meeting full disorder criteria. Specific anxiety subtypes: generalized anxiety disorder; diabetes-specific distress (about 30-45% prevalence); hypoglycemia anxiety (particularly common in type 1 diabetes and insulin users); needle/blood phobia; panic disorder; social anxiety related to diabetes management. Impact: poor glycemic control; avoidance of self-monitoring; reluctance to take medications appropriately (especially insulin); avoidance of healthcare appointments; worse complications. Bidirectional — diabetes worsens anxiety; anxiety worsens diabetes outcomes. Diabetes distress (DDS-17) refers to emotional burden specifically related to living with diabetes — worry about complications, fatigue from constant self-management, frustration with healthcare system, social burden. Different from clinical depression or anxiety disorder. About 30-45% of adults with diabetes have elevated diabetes distress. Treatment: diabetes-specific cognitive behavioral therapy; diabetes self-management education; peer support groups; addressing specific concerns; not always pharmacologic. Effective treatments available. Severity-based approach: mild — watchful waiting and lifestyle; moderate — treatment plan with psychotherapy preferred initially; severe — active treatment with combination approach often. Psychotherapy options: cognitive behavioral therapy (CBT) first-line for anxiety; exposure therapy for phobias; mindfulness-based stress reduction; acceptance and commitment therapy. Medication options: SSRIs (escitalopram, sertraline) first-line; SNRIs (duloxetine — bonus for diabetic neuropathy, venlafaxine); buspirone; avoid long-term benzodiazepines (dependence risk, fall risk in older adults, less effective for chronic anxiety). Diabetes-specific approach: hypoglycemia anxiety — CGM device may help, technology assistance reduces fear, diabetes education; needle anxiety — pen devices, technique training, gradual exposure. Lifestyle: regular exercise (proven anxiolytic effect), sleep, limit caffeine/alcohol, mindfulness practice, yoga. Refer mental health specialist for severe or complex cases. For adults with type 2 diabetes — ensure your provider screens for both anxiety and diabetes-specific distress; if positive, effective treatments available; addressing anxiety improves quality of life and diabetes outcomes. See our broader diabetes complications guide for context.

The PHQ-9 (Patient Health Questionnaire-9) is a 9-item depression screening and severity measurement tool widely used in primary care. Format: self-administered questionnaire; takes 2-3 minutes; can be completed on paper, electronically, or verbally; each item asks about frequency of depression symptoms over the past 2 weeks. The 9 items match DSM diagnostic criteria for major depression: little interest or pleasure in doing things (anhedonia); feeling down, depressed, or hopeless; trouble falling asleep, staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself — failure or letting yourself or family down; trouble concentrating on things; moving or speaking so slowly others noticed, or being fidgety/restless; thoughts of being better off dead or hurting yourself. Each scored 0 (not at all) to 3 (nearly every day); total 0-27. Validated, freely available, no licensing fee. Depression and diabetes have bidirectional relationship with major consequences. Statistics: depression affects 15-30% of adults with type 2 diabetes (2x general population rate); depression often unrecognized in diabetes care. Impact: worse glycemic control (depression linked to higher A1C, more variability); worse self-management (less exercise, less medication adherence, less glucose monitoring); higher complication rates (heart disease, neuropathy, nephropathy); higher mortality (increased CV and all-cause mortality); worse quality of life; higher healthcare costs; increased risk for type 2 diabetes onset (in non-diabetic depressed individuals). Possible mechanisms: depression-related lifestyle factors (poor diet, inactivity, smoking); HPA axis dysregulation (cortisol elevation worsens insulin resistance); chronic inflammation; sleep disruption; effects of antidepressant medications on weight and glucose. ADA recommends screening at diabetes diagnosis and at least annually thereafter, plus during life changes and complications. Effective treatment improves both depression and diabetes outcomes. Scoring: sum item scores (0-3 each); total 0-27. Severity categories: 0-4 minimal depression (no treatment needed); 5-9 mild depression (watchful waiting; repeat in 2-4 weeks); 10-14 moderate depression (treatment plan; consider counseling, possible antidepressant); 15-19 moderately severe depression (active treatment); 20-27 severe depression (active treatment; consider specialist referral). Special considerations: Item 9 (suicidal thoughts) — ALWAYS triggers immediate attention regardless of total score; ask about suicide intent, plan, means; safety assessment; emergency evaluation if needed. PHQ-2 — shorter 2-item version (items 1-2); preliminary screen; if positive proceeds to full PHQ-9. Use over time: serial PHQ-9 tracks treatment response.

PHQ-9 Score Interpretation

Depression and Diabetes Statistics

Treatment Options for Diabetes-Comorbid Depression

• Psychotherapy — CBT, behavioral activation, interpersonal therapy.
• SSRIs — sertraline (Zoloft), escitalopram (Lexapro) — first-line generally.
• SNRIs — duloxetine (Cymbalta) — also treats diabetic neuropathy.
• Bupropion (Wellbutrin) — weight-neutral or weight loss; energy effect.
• Avoid for weight gain — paroxetine (Paxil), mirtazapine (Remeron).
• Combination therapy — medication + psychotherapy often more effective.
• Exercise — proven antidepressant effect; also benefits diabetes.
• Diabetes-specific cognitive behavioral therapy (CBT-D) — emerging evidence.
• Address sleep disturbance.
• Support groups (in-person or online).
• Mindfulness-based approaches.
• Refer to mental health specialist for severe or treatment-resistant depression.

The 9 PHQ-9 Items (Past 2 Weeks)

• Little interest or pleasure in doing things.
• Feeling down, depressed, or hopeless.
• Trouble falling/staying asleep or sleeping too much.
• Feeling tired or having little energy.
• Poor appetite or overeating.
• Feeling bad about yourself — failure or let yourself/family down.
• Trouble concentrating (reading, watching TV).
• Moving/speaking slowly or being fidgety/restless.
• Thoughts of being better off dead or hurting yourself.

Suicide Safety Assessment

• Item 9 positive (any score 1-3) — always assess further.
• Ask directly: “Are you having thoughts of suicide?”
• Assess: intent, plan, means, prior attempts.
• Safety plan: remove access to means (firearms, medications).
• Crisis resources: 988 Suicide and Crisis Lifeline.
• Emergency department for active suicidal intent.
• Inpatient psychiatric care if imminent danger.
• Provider follow-up arranged before patient leaves.
• Family/support person involvement.

The Bottom Line

The PHQ-9 (Patient Health Questionnaire-9) is a 9-item depression screening and severity measurement tool widely used in primary care. Format: self-administered questionnaire; takes 2-3 minutes; can be completed on paper, electronically, or verbally; each item asks about frequency of depression symptoms over the past 2 weeks. The 9 items match DSM diagnostic criteria for major depression: little interest or pleasure in doing things (anhedonia); feeling down, depressed, or hopeless; trouble falling asleep, staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself; trouble concentrating; moving or speaking so slowly others noticed (or being fidgety/restless); thoughts of being better off dead or hurting yourself. Each scored 0 (not at all) to 3 (nearly every day); total 0-27. Validated, freely available, no licensing fee. Depression and diabetes have bidirectional relationship with major consequences. Statistics: depression affects 15-30% of adults with type 2 diabetes (2x general population rate); depression often unrecognized in diabetes care. Impact: worse glycemic control; worse self-management (less exercise, less medication adherence, less glucose monitoring); higher complication rates; higher mortality; worse quality of life; higher healthcare costs. Possible mechanisms: depression-related lifestyle factors; HPA axis dysregulation (cortisol elevation worsens insulin resistance); chronic inflammation; sleep disruption; effects of antidepressant medications on weight and glucose. ADA recommends screening at diabetes diagnosis and at least annually thereafter, plus during life changes and complications. Effective treatment improves both depression and diabetes outcomes. Severity categories: 0-4 minimal depression; 5-9 mild depression (watchful waiting; repeat in 2-4 weeks); 10-14 moderate depression (treatment plan); 15-19 moderately severe depression (active treatment); 20-27 severe depression (active treatment; consider specialist referral). Special considerations: Item 9 (suicidal thoughts) — ALWAYS triggers immediate attention regardless of total score; ask about suicide intent, plan, means; safety assessment; emergency evaluation if needed. Multiple effective treatment options: psychotherapy (CBT, behavioral activation, interpersonal therapy); SSRIs (sertraline, escitalopram) first-line generally; SNRIs (duloxetine — bonus for diabetic neuropathy pain); bupropion (weight-neutral or weight loss); avoid weight gain — paroxetine, mirtazapine; combination therapy often more effective; lifestyle approaches (regular exercise — proven antidepressant; sleep hygiene; social connection; mindfulness); diabetes management improving glycemic control may improve mood. Crisis resources: 988 Suicide and Crisis Lifeline for urgent help. Treatment works — most people improve. For adults with type 2 diabetes — ensure your provider screens at least annually with PHQ-9 or similar tool; if positive, follow through with treatment; depression treatment improves both quality of life and diabetes outcomes. See our broader diabetes complications guide for context.

Fundus photography is a specialized photographic technique that captures color images of the back of the eye — including the retina, optic disc, macula, and retinal blood vessels. Procedure: patient sits in front of fundus camera (similar to a regular camera but larger and more specialized); chin rest and forehead bar position head; bright flash illuminates retina; camera captures high-resolution image through pupil; takes seconds per image. Two types: mydriatic (requires pupil dilation with drops; wider field of view; more detail) and non-mydriatic (no dilation required; specialized cameras work through small pupils; faster; ideal for screening; some image quality compromise). Uses: documentation of retinopathy findings; baseline images for comparison; screening for diabetic retinopathy; remote interpretation (telemedicine); AI-based automated analysis; macular evaluation; optic nerve documentation (glaucoma, optic neuritis). Provides 2D color image; less detailed than OCT (which shows layers) but provides important screening information. Primary tool for telemedicine-based DR screening. Standard protocol: patient sits for fundus camera (typically non-mydriatic); 1-7 images taken per eye depending on protocol; images transmitted electronically to grading center or specialist; trained graders or ophthalmologists review images; results returned to primary care; patient notified; referral to retina specialist if abnormal. Settings: primary care offices, endocrinology clinics, pharmacies (some), retail eye clinics, mobile screening units, telemedicine programs (especially rural/underserved). Advantages: increases access (no need for ophthalmologist visit for screening); cost-effective; rapid; integrates into primary care workflow. Limitations: limited to retinal surface (no cross-sectional info like OCT); image quality affected by cataracts, small pupils, media opacity; misses some peripheral lesions; cannot evaluate vitreoretinal interface. American Diabetes Association supports fundus photography screening with appropriate quality control. Newer AI systems (IDx-DR, EyeArt) FDA-approved for automated interpretation in primary care. AI-based interpretation: FDA-approved systems include IDx-DR (now Digital Diagnostics — first FDA-approved AI device for diabetic retinopathy screening in 2018; designed for primary care offices; gives results in minutes; reports “no more than mild DR” or “more than mild DR — refer to eye care professional”; sensitivity about 87%, specificity 91%) and EyeArt (FDA-approved 2020; similar primary care indication; high sensitivity for referable DR). How they work: trained on thousands of fundus images labeled by ophthalmologists; deep learning neural networks; identify features associated with DR. Advantages: instant results; no specialist needed for screening; standardized interpretation; expands access in underserved areas. Limitations: not yet for monitoring or treatment decisions; some image quality requirements; not all patients eligible (need clear media, no significant other eye disease); cost considerations. Implementation: primary care offices, federally qualified health centers, integrated health systems. Growing role in primary care diabetic retinopathy screening — making annual screening practical.

Fundus Photography Modalities

Diabetic Retinopathy Findings on Fundus Photos

Telemedicine Screening Programs

• VA (Veterans Affairs) — large teleretinal screening program.
• IHS (Indian Health Service) — mobile fundus screening in Native communities.
• EyePACS — store-and-forward telemedicine platform.
• State diabetes screening programs.
• Walmart Vision Centers (some).
• Primary care office screening with AI interpretation.
• Federally Qualified Health Centers (FQHCs).
• Increases adherence to annual DR screening dramatically.
• Cost-effective and proven to reduce vision loss.

AI Interpretation Limitations

• Not for monitoring established retinopathy.
• Not for treatment decisions.
• Image quality requirements (clear media).
• Not for patients with other significant eye disease.
• Cannot replace comprehensive eye exam in patients with symptoms.
• Not currently for pregnancy-related screening.
• FDA-approved for type 2 diabetes; some validation for type 1.
• Insurance coverage variable.
• Still requires referral if abnormal.

Screening Recommendations

• Type 2 diabetes — annual eye exam (or AI-interpreted fundus photo if available).
• Type 1 diabetes — annual exam starting 5 years after diagnosis.
• Pregnant women with pre-existing diabetes — every trimester.
• Mild DR — annual.
• Moderate DR — every 6-12 months.
• Severe non-proliferative DR — every 3-6 months.
• Proliferative DR — every 1-3 months until controlled.
• Macular edema — every 1-3 months during treatment.

The Bottom Line

Fundus photography is a specialized photographic technique that captures color images of the back of the eye — including the retina, optic disc, macula, and retinal blood vessels. Procedure: patient sits in front of fundus camera; chin rest and forehead bar position head; bright flash illuminates retina; camera captures high-resolution image through pupil; takes seconds per image. Two types: mydriatic (requires pupil dilation with drops; wider field of view; more detail) and non-mydriatic (no dilation required; specialized cameras work through small pupils; faster; ideal for screening; some image quality compromise). Uses: documentation of retinopathy findings; baseline images for comparison; screening for diabetic retinopathy; remote interpretation (telemedicine); AI-based automated analysis; macular evaluation; optic nerve documentation. Provides 2D color image; less detailed than OCT but provides important screening information. Primary tool for telemedicine-based DR screening. Standard protocol: patient sits for fundus camera (typically non-mydriatic); 1-7 images taken per eye; images transmitted electronically to grading center or specialist; trained graders or ophthalmologists review images; results returned to primary care; patient notified; referral to retina specialist if abnormal. Settings: primary care offices, endocrinology clinics, pharmacies (some), retail eye clinics, mobile screening units, telemedicine programs (especially rural/underserved). Advantages: increases access (no need for ophthalmologist visit for screening); cost-effective; rapid; integrates into primary care workflow. Limitations: limited to retinal surface; image quality affected by cataracts, small pupils, media opacity; misses some peripheral lesions; cannot evaluate vitreoretinal interface. American Diabetes Association supports fundus photography screening with appropriate quality control. AI systems (IDx-DR, EyeArt) FDA-approved for automated interpretation in primary care. IDx-DR — first FDA-approved AI device for diabetic retinopathy screening (2018); designed for primary care offices; gives results in minutes; reports “no more than mild DR” or “more than mild DR — refer to eye care professional”; sensitivity about 87%, specificity 91%. EyeArt — FDA-approved 2020; similar primary care indication; high sensitivity for referable DR. How they work: trained on thousands of fundus images labeled by ophthalmologists; deep learning neural networks; identify features associated with DR. Advantages: instant results; no specialist needed for screening; standardized interpretation; expands access. Limitations: not for monitoring or treatment decisions; image quality requirements; not all patients eligible. Procedure expectations: brief, comfortable, non-invasive; technician explains procedure; sit in front of camera; place chin on chin rest and forehead against bar; bright flash for each image; takes a few seconds; multiple images of each eye usually (1-7 per eye); bright spots in vision briefly; resume normal activities. Frequency: annual for adults with diabetes meeting screening criteria; more frequently if retinopathy present. For adults with type 2 diabetes — annual fundus photography or comprehensive eye exam is essential; ask your primary care provider whether your clinic offers fundus photo screening for convenience. See our broader diabetic retinopathy guide for context.

DEXA (dual-energy X-ray absorptiometry) is a low-radiation X-ray scan that measures bone mineral density (BMD). Procedure: lie flat on padded table; scanner arm passes over body without touching; X-rays measure bone density at standard sites (lumbar spine and hip most commonly; sometimes forearm or whole body); takes 10-30 minutes total; very low radiation (less than chest X-ray). Results: T-score (compared to healthy young adult — used to diagnose osteoporosis): normal greater than -1.0; osteopenia (low bone mass) -1.0 to -2.5; osteoporosis -2.5 or below. Z-score (compared to age-matched peers — used in younger adults, children). FRAX tool: combines BMD with clinical risk factors to estimate 10-year fracture probability. Uses: diagnose osteoporosis; assess fracture risk; monitor response to osteoporosis treatment; baseline before glucocorticoid therapy. Standard guidelines apply with diabetes adding to risk factors. USPSTF/NOF recommendations: all women age 65+ — routine screening; men age 70+ — routine screening; younger postmenopausal women (50-64) with risk factors — screen; men 50-69 with risk factors — screen. Risk factors include: history of fracture as adult, family history of osteoporosis or hip fracture, low body weight, smoking, alcohol excess, glucocorticoid use, certain medications (aromatase inhibitors, GnRH agonists), various conditions. Diabetes considerations: type 1 diabetes — higher fracture risk; consider earlier screening (age 50 for postmenopausal women); type 2 diabetes — fracture risk modestly elevated despite often normal DEXA; standard screening intervals usually appropriate; long-standing diabetes complications (neuropathy, retinopathy, vascular disease) increase fall risk; certain diabetes medications affect bone — thiazolidinediones (pioglitazone) increase fracture risk; SGLT2 inhibitors mixed evidence (canagliflozin initially flagged but later studies less concerning). The paradox: type 2 diabetes adults often have NORMAL or HIGHER bone mineral density on DEXA but 50-100% increased fracture risk. Possible explanations: bone QUALITY (not quantity) — diabetic bone has abnormal collagen crosslinks; advanced glycation end products (AGEs) accumulate in bone matrix; bone is more brittle despite normal density. Increased fall risk — neuropathy (peripheral and autonomic — affecting balance, postural blood pressure); retinopathy (vision impairment); cardiovascular disease; medications causing hypoglycemia (which causes falls); polypharmacy. Slower bone turnover — diabetes may suppress bone formation more than resorption. Vascular changes affecting bone perfusion. Trabecular bone score (TBS) — texture measurement from DEXA — often abnormal in diabetes even with normal BMD; helps identify diabetes-related bone fragility. Vitamin D deficiency more common. Some diabetes medications affect bone (thiazolidinediones especially). Type 1 diabetes shows both low BMD AND increased fracture risk — different mechanism (insulin deficiency affects bone formation since childhood/adolescence).

DEXA Score Interpretation

Screening Recommendations

Diabetes and Fracture Risk Paradox

• Type 2 diabetes — often NORMAL or HIGH bone density.
• BUT 50-100% increased fracture risk.
• Cause: bone QUALITY abnormal (not quantity).
• Advanced glycation end products (AGEs) make bone brittle.
• Increased fall risk from neuropathy, retinopathy.
• Hypoglycemia from medications causes falls.
• Vascular disease affects bone perfusion.
• Slower bone formation.
• Trabecular bone score (TBS) — texture measure — often low.
• Type 1 diabetes — lower BMD AND higher fractures.

Diabetes Medications and Bone

• Thiazolidinediones (pioglitazone) — increase fracture risk, especially in women.
• SGLT2 inhibitors (canagliflozin) — initially flagged; later studies less concerning.
• Metformin — neutral; possible mild bone protection.
• Sulfonylureas — hypoglycemia → fall risk.
• Insulin — hypoglycemia → fall risk.
• DPP-4 inhibitors — neutral.
• GLP-1 agonists — neutral or possibly beneficial.
• Discuss with prescriber if osteoporosis present.

Fall Prevention for Adults with Diabetes

• Address vision changes (annual eye exam).
• Manage neuropathy and balance issues (physical therapy).
• Avoid hypoglycemia (medication review).
• Home safety: remove rugs, install grab bars, improve lighting.
• Strength and balance exercise (tai chi, yoga).
• Adequate vitamin D and calcium.
• Medication review (orthostatic hypotension, sedatives).
• Address foot pain promptly.
• Appropriate footwear.
• Cane or walker if balance issues.
• Annual fall risk assessment.

The Bottom Line

DEXA (dual-energy X-ray absorptiometry) is a low-radiation X-ray scan that measures bone mineral density (BMD). Procedure: lie flat on padded table; scanner arm passes over body without touching; X-rays measure bone density at standard sites (lumbar spine and hip most commonly; sometimes forearm or whole body); takes 10-30 minutes total; very low radiation (less than chest X-ray). Results: T-score (compared to healthy young adult — used to diagnose osteoporosis): normal greater than -1.0; osteopenia (low bone mass) -1.0 to -2.5; osteoporosis -2.5 or below. Z-score (compared to age-matched peers). FRAX tool: combines BMD with clinical risk factors to estimate 10-year fracture probability. Uses: diagnose osteoporosis; assess fracture risk; monitor response to osteoporosis treatment; baseline before glucocorticoid therapy. Standard guidelines apply with diabetes adding to risk factors. USPSTF/NOF recommendations: all women age 65+ — routine screening; men age 70+ — routine screening; younger postmenopausal women (50-64) with risk factors — screen; men 50-69 with risk factors — screen. Diabetes considerations: type 1 diabetes — higher fracture risk; consider earlier screening; type 2 diabetes — fracture risk modestly elevated despite often normal DEXA; standard screening intervals usually appropriate; long-standing diabetes complications (neuropathy, retinopathy, vascular disease) increase fall risk; certain diabetes medications affect bone — thiazolidinediones (pioglitazone) increase fracture risk. The paradox: type 2 diabetes adults often have NORMAL or HIGHER bone mineral density on DEXA but 50-100% increased fracture risk. Possible explanations: bone QUALITY (not quantity) — diabetic bone has abnormal collagen crosslinks; advanced glycation end products (AGEs) accumulate in bone matrix; bone is more brittle despite normal density. Increased fall risk — neuropathy, retinopathy, cardiovascular disease, hypoglycemia from medications, polypharmacy. Slower bone turnover. Vascular changes affecting bone perfusion. Trabecular bone score (TBS) — texture measurement from DEXA — often abnormal in diabetes even with normal BMD. Vitamin D deficiency more common. Type 1 diabetes shows both low BMD AND increased fracture risk. Procedure: no special diet or fasting; avoid calcium supplements 24 hours before; wear loose clothing without metal on torso; lie on padded scan table; arm of scanner moves over body; technologist positions body for spine and hip scans; total scan time 10-30 minutes; no contact with body; no pain. Results: usually within 1-3 days; T-score and Z-score reported; FRAX 10-year fracture risk often calculated. Fall prevention important: address vision changes; manage neuropathy and balance issues; avoid hypoglycemia; home safety modifications; strength and balance exercise; adequate vitamin D and calcium; medication review; appropriate footwear. For adults with diabetes — discuss bone health with provider, address modifiable risk factors, follow standard DEXA screening guidelines plus diabetes-specific considerations. See our broader prediabetes detection guide.

OCT (optical coherence tomography) is a non-invasive imaging test that uses light waves to create cross-sectional images of the retina, similar to ultrasound but using light instead of sound. The technology provides extremely detailed visualization of retinal layers — like a “biopsy” of the retina without actually taking tissue. Procedure: pupils may or may not be dilated; chin rest and forehead bar position the head; you stare at a fixation target; scanner captures images in 5-10 seconds per eye; computer generates cross-sectional views showing retinal layers; total appointment 15-30 minutes including dilation. Image resolution: 5-7 micrometers (much finer than ophthalmoscopy). Provides: layer-by-layer retinal anatomy; central retinal thickness measurements; macular volume; nerve fiber layer thickness; vitreoretinal interface assessment. Non-invasive nature makes it ideal for repeated monitoring. Central tool for diabetic macular edema (DME) management. Specific uses: diagnose DME (primary use — detects retinal thickening and intraretinal fluid before visible on standard exam); measure central retinal thickness (quantitative measurement; normal about 250 micrometers; DME defined as more than 300 micrometers in many studies); identify subretinal fluid (fluid beneath retina); detect intraretinal cysts (fluid-filled spaces); evaluate vitreomacular traction (pulling of vitreous on retina); identify epiretinal membrane (scar tissue on retinal surface); monitor treatment response (repeat OCT after anti-VEGF injections, laser, or steroids); distinguish edema causes (diabetic vs other — vein occlusion, age-related macular degeneration). Standard frequency: at diagnosis of DR; every 3-6 months if DME present; more frequently during active treatment. OCT increasingly replaces clinical exam alone for DME monitoring. OCT angiography (OCTA) — newer non-invasive extension that visualizes blood flow without dye injection. Technology: rapidly repeated OCT scans of same location; motion contrast detects blood flow (moving cells); generates depth-resolved vascular maps; no dye injection needed; about 5 seconds per eye. Advantages over fluorescein angiography (FA): no needle/IV; no dye reactions; no nausea or skin discoloration; can repeat as often as needed; layer-specific visualization (separate superficial and deep capillary plexus); shows foveal avascular zone clearly; faster procedure. Limitations: cannot show leakage (no dye to leak — only structural vasculature); limited field of view in many devices; image artifacts can occur; less established for guiding pan-retinal photocoagulation. Indications for OCTA in diabetes: evaluate macular capillary changes; monitor for neovascularization without dye; quantify foveal avascular zone (FAZ) enlargement (marker of DR severity); detect retinal nonperfusion. Increasingly used; not yet fully replaced FA.

OCT Uses in Diabetic Retinopathy

OCT vs Other Eye Imaging

Diabetic Macular Edema Findings on OCT

• Increased central retinal thickness (greater than 300 micrometers usually).
• Intraretinal cysts (round dark spaces in retina).
• Subretinal fluid (fluid beneath retina).
• Hard exudates (bright spots — lipid deposits).
• Disorganization of retinal inner layers (DRIL — affects vision prognosis).
• Loss of foveal depression (when severe).
• Vitreomacular traction (if present).

Treatment Monitoring Pattern

• Baseline OCT before starting treatment.
• OCT 4-6 weeks after each anti-VEGF injection.
• Decision based on OCT findings: continue if edema persists; extend interval if improved; switch agent if no response.
• Stable disease: OCT every 3-6 months.
• Active treatment: OCT monthly often.
• Vision and OCT both considered in treatment decisions.
• Diabetes management critical — OCT improvements correlate with glycemic improvement.

When OCT Is Performed

• At diagnosis of diabetic retinopathy.
• Annually for mild non-proliferative DR.
• Every 6 months for moderate to severe non-proliferative DR.
• Every 3 months for proliferative DR or DME.
• Before and after anti-VEGF injections.
• Before and after laser treatment.
• Whenever vision changes occur.
• Pre-operative planning for vitreoretinal surgery.

The Bottom Line

OCT (optical coherence tomography) is a non-invasive imaging test that uses light waves to create cross-sectional images of the retina, similar to ultrasound but using light instead of sound. The technology provides extremely detailed visualization of retinal layers — like a “biopsy” of the retina without actually taking tissue. Procedure: pupils may or may not be dilated; chin rest and forehead bar position the head; you stare at a fixation target; scanner captures images in 5-10 seconds per eye; computer generates cross-sectional views showing retinal layers; total appointment 15-30 minutes including dilation. Image resolution: 5-7 micrometers (much finer than ophthalmoscopy). Provides: layer-by-layer retinal anatomy; central retinal thickness measurements; macular volume; nerve fiber layer thickness; vitreoretinal interface assessment. Central tool for diabetic macular edema (DME) management. Specific uses: diagnose DME (primary use — detects retinal thickening and intraretinal fluid before visible on standard exam); measure central retinal thickness (quantitative measurement; normal about 250 micrometers; DME defined as more than 300 micrometers in many studies); identify subretinal fluid; detect intraretinal cysts; evaluate vitreomacular traction; identify epiretinal membrane; monitor treatment response after anti-VEGF injections, laser, or steroids; distinguish edema causes (diabetic vs other — vein occlusion, age-related macular degeneration). Standard frequency: at diagnosis of DR; every 3-6 months if DME present; more frequently during active treatment. OCT increasingly replaces clinical exam alone for DME monitoring. OCT angiography (OCTA) — newer non-invasive extension that visualizes blood flow without dye injection. Technology: rapidly repeated OCT scans of same location; motion contrast detects blood flow; generates depth-resolved vascular maps; no dye injection needed; about 5 seconds per eye. Advantages over fluorescein angiography (FA): no needle/IV; no dye reactions; no nausea or skin discoloration; can repeat as often as needed; layer-specific visualization; shows foveal avascular zone clearly; faster procedure. Limitations: cannot show leakage (no dye to leak — only structural vasculature); limited field of view in many devices; image artifacts can occur; less established for guiding pan-retinal photocoagulation. Indications for OCTA in diabetes: evaluate macular capillary changes; monitor for neovascularization without dye; quantify foveal avascular zone (FAZ) enlargement (marker of DR severity); detect retinal nonperfusion. Increasingly used; not yet fully replaced FA. Procedure expectations: brief, comfortable, non-invasive; minimal preparation; eat normally; take medications; bring sunglasses if dilation expected; scan takes 5-10 seconds per eye; total appointment 15-30 minutes; no contact with eye; no pain; results discussed during same visit. Frequency for diabetes: every 6-12 months for stable retinopathy; every 1-3 months during active DME treatment. For adults with type 2 diabetes — OCT is essential tool for retinopathy monitoring; ask retina specialist about OCT findings at each visit. See our broader diabetic retinopathy guide for context.

Fluorescein angiography (FA) is a specialized eye imaging test that uses a fluorescent dye (sodium fluorescein) injected into a vein to visualize blood vessels in the retina and choroid. Procedure: pupils dilated; baseline photos taken; fluorescein dye (5 mL typically) injected into arm vein; series of rapid retinal photographs taken as dye travels through retinal blood vessels (about 30 seconds for dye to reach eyes); imaging continues for 5-10 minutes capturing dye filling and leaking phases; late photos at 10-15 minutes. Demonstrates: blood vessel anatomy and integrity; areas of leakage (broken blood vessels); areas of nonperfusion/ischemia (no blood supply); neovascularization (abnormal new vessels); microaneurysms. Total appointment: about 60-90 minutes including dilation. Performed at retina specialist or ophthalmologist office with imaging equipment. Used to evaluate moderate to severe retinopathy and guide treatment. Indications: determine extent of retinal nonperfusion/ischemia (cannot be seen on regular exam); identify and locate microaneurysms or abnormal vessels needing laser treatment; evaluate diabetic macular edema (often combined with OCT); detect neovascularization (abnormal blood vessels — proliferative diabetic retinopathy); plan and guide focal laser photocoagulation; monitor response to anti-VEGF treatment; pre-operative planning for vitreoretinal surgery. NOT used for: routine retinopathy screening (use color photographs or comprehensive exam); mild non-proliferative retinopathy without macular involvement. Increasingly replaced/supplemented by OCT angiography (OCTA) — dye-free; less invasive; lower spatial resolution but no needle/dye risks. Indications for FA narrowing as OCTA improves. Preparation: schedule with someone to drive you home (pupils dilated 4-6 hours afterward affects vision); arrive 15-20 minutes early; bring sunglasses for after; eat normally; take medications as usual. Procedure: pupils dilated with drops (15-20 minutes); brief baseline retinal photos; IV line placed in arm (small needle); fluorescein dye injected over 5-10 seconds; rapid retinal photos begin immediately as dye reaches eyes; you’ll see bright flashes from the camera (uncomfortable but tolerable); imaging continues for 5-10 minutes; late photos at 10-15 minutes; total imaging time about 30 minutes. Possible sensations: brief warmth and unusual taste as dye injected; sometimes nausea (lasts minutes); occasional sneezing. After: yellow tint to skin (lasts 6-12 hours); bright yellow urine (lasts 24-48 hours); pupils stay dilated 4-6 hours.

FA Indications in Diabetic Retinopathy

What FA Shows

FA Side Effects and Risks

• Yellow skin tint (lasts 6-12 hours) — common, expected.
• Bright yellow urine (lasts 24-48 hours) — common.
• Pupil dilation aftereffects (4-6 hours).
• Brief warmth and unusual taste during injection (~30%).
• Nausea (~5%) — usually brief.
• Sneezing during injection — common, harmless.
• Vasovagal reaction (lightheadedness, fainting) — rare.
• Hives, itching (~1%).
• Extravasation (dye outside vein) — yellow skin at site for days.
• Severe allergic reaction (anaphylaxis) — about 1 in 200,000.
• Death — extremely rare (~1 in 220,000).
• Emergency equipment and antihistamines available at every facility.

FA vs OCT Angiography (OCTA)

• FA — dye-based; whole retinal vasculature; gold standard; invasive (IV needle, dye).
• OCTA — dye-free; layer-by-layer vascular imaging; non-invasive; takes seconds.
• OCTA limited to macular area in many devices.
• OCTA cannot show leakage (no dye to leak).
• FA still gold standard for leakage assessment.
• OCTA increasingly used for routine vascular assessment.
• Combination of OCT, OCTA, and color photos sufficient for many cases.
• FA reserved for treatment planning and complex cases.

Preparation Checklist

• Bring someone to drive you home.
• Bring sunglasses for after dilation.
• Eat normally before procedure.
• Take medications as usual.
• Bring list of allergies (especially iodine, contrast dye).
• Inform staff if pregnant or possibly pregnant.
• Inform staff of kidney disease.
• Hydrate well before procedure.
• Allow 60-90 minutes total time.
• Wear easy-to-roll-up sleeve.

The Bottom Line

Fluorescein angiography (FA) is a specialized eye imaging test that uses a fluorescent dye (sodium fluorescein) injected into a vein to visualize blood vessels in the retina and choroid. Procedure: pupils dilated; baseline photos taken; fluorescein dye (5 mL typically) injected into arm vein; series of rapid retinal photographs taken as dye travels through retinal blood vessels (about 30 seconds for dye to reach eyes); imaging continues for 5-10 minutes capturing dye filling and leaking phases; late photos at 10-15 minutes. Demonstrates: blood vessel anatomy and integrity; areas of leakage (broken blood vessels); areas of nonperfusion/ischemia (no blood supply); neovascularization (abnormal new vessels); microaneurysms. Total appointment: about 60-90 minutes including dilation. Performed at retina specialist or ophthalmologist office. Used to evaluate moderate to severe retinopathy and guide treatment. Indications: determine extent of retinal nonperfusion/ischemia (cannot be seen on regular exam); identify and locate microaneurysms or abnormal vessels needing laser treatment; evaluate diabetic macular edema (often combined with OCT); detect neovascularization (abnormal blood vessels — proliferative diabetic retinopathy); plan and guide focal laser photocoagulation; monitor response to anti-VEGF treatment; pre-operative planning for vitreoretinal surgery. NOT used for routine retinopathy screening or mild non-proliferative retinopathy without macular involvement. Increasingly replaced/supplemented by OCT angiography (OCTA) — dye-free; less invasive; lower spatial resolution but no needle/dye risks. Preparation: schedule with someone to drive you home; arrive 15-20 minutes early; bring sunglasses for after; eat normally; take medications as usual. Procedure: pupils dilated with drops (15-20 minutes); brief baseline retinal photos; IV line placed in arm; fluorescein dye injected over 5-10 seconds; rapid retinal photos begin immediately; imaging continues for 5-10 minutes; late photos at 10-15 minutes; total imaging time about 30 minutes. Possible sensations: brief warmth and unusual taste as dye injected; sometimes nausea (lasts minutes); occasional sneezing. After: yellow tint to skin (lasts 6-12 hours); bright yellow urine (lasts 24-48 hours); pupils stay dilated 4-6 hours. Side effects: nausea (~5%), itchy skin (~1%), severe reactions (anaphylaxis) rare but possible (1 in 200,000). Contraindications: severe allergy to fluorescein, pregnancy (relative), severe kidney disease (relative). For adults with type 2 diabetes — FA is used when retinopathy treatment decisions need vascular detail; not used for routine screening; discuss with retina specialist if recommended. See our broader diabetic retinopathy guide for context.

Skin cancer screening involves examination of skin for suspicious lesions — moles, growths, sores that might be cancerous. Two main approaches. Self-exam — examine your own skin monthly using mirror or partner help; check all areas including back, scalp, between toes, soles of feet, genitals; look for new lesions or changes in existing ones using ABCDE criteria. Clinician skin exam (CSE) — performed by dermatologist or primary care provider; full-body inspection; dermatoscope (specialized magnifier) used to evaluate suspicious lesions; biopsy any suspicious lesions. Skin cancers screened: basal cell carcinoma (most common; rarely metastasizes; usually curable); squamous cell carcinoma (second most common; can metastasize especially if neglected); melanoma (less common but most deadly; early detection critical). USPSTF 2023 conclusion — insufficient evidence to recommend FOR or AGAINST screening in asymptomatic adults; risk-based approach commonly used. Modestly elevated risk in diabetes, especially for non-melanoma types. Studies suggest: squamous cell carcinoma — about 15-20% increased risk in adults with type 2 diabetes; basal cell carcinoma — about 10% increased risk; melanoma — possibly modest increased risk; less clear. Possible mechanisms: hyperinsulinemia and IGF-1 promoting tumor growth; chronic inflammation; immune dysfunction; oxidative stress; possible direct hyperglycemia effects; some diabetes medications (especially pioglitazone — possible bladder cancer; SGLT2 inhibitors and metformin appear neutral or possibly protective). However, sun exposure remains by far the dominant skin cancer risk factor; diabetes is much smaller contributor. Highest risk individuals: fair skin, history of sunburns, lots of moles, family history of melanoma, immunosuppression, prior skin cancer. Risk reduction: sun protection (SPF 30+ daily, hats, long sleeves), avoid tanning beds, regular self-exams, dermatologist visit if high risk. Diabetes-associated skin conditions warrant monitoring: acanthosis nigricans (dark velvety patches in skin folds — marker of insulin resistance; not cancer); diabetic dermopathy (light brown round/oval scaly patches on shins — common in long-standing diabetes; benign); necrobiosis lipoidica diabeticorum (NLD — yellow-brown patches with raised borders, often on shins; uncommon but classic for diabetes; can ulcerate); diabetic bullae (spontaneous blisters); eruptive xanthomas (from very high triglycerides); skin tags (common with insulin resistance); diabetic ulcers (especially foot ulcers — serious complications). Cancer concerns: NLD lesions can rarely develop squamous cell carcinoma — monitor; chronic non-healing diabetic ulcers can develop squamous cell carcinoma in long-standing cases.

ABCDE Melanoma Warning Signs

Common Skin Cancers

Diabetes-Related Skin Conditions

• Acanthosis nigricans — insulin resistance marker; not cancer.
• Diabetic dermopathy — shin spots; benign.
• Necrobiosis lipoidica — uncommon; rarely transforms; monitor.
• Diabetic bullae — spontaneous blisters; usually heal.
• Eruptive xanthomas — high triglycerides; resolves with treatment.
• Skin tags — insulin resistance association.
• Diabetic foot ulcers — serious; squamous cell carcinoma risk in chronic ulcers.
• Granuloma annulare — possible diabetes association.
• Yellow skin (carotenemia) — sometimes diabetes-related.
• Vitiligo — autoimmune; more common with type 1 diabetes.
• Fungal infections — more common in poorly controlled diabetes.

Skin Self-Exam Steps

• Stand in front of full-length mirror in well-lit room.
• Examine face, neck, ears, scalp (part hair to look).
• Check chest, abdomen, and front of legs.
• Use hand mirror to check back, buttocks.
• Examine arms (front and back), hands (including between fingers).
• Sit and check tops/bottoms of feet, between toes.
• Check legs front and back.
• Examine genitals and area around them.
• Photograph existing moles to track changes.
• Monthly self-exam recommended for high-risk individuals.
• Have partner help with hard-to-see areas.

Sun Protection

• SPF 30+ broad-spectrum sunscreen daily.
• Reapply every 2 hours and after swimming/sweating.
• Hat (wide-brim preferred).
• UV-blocking sunglasses.
• Long sleeves and pants when feasible.
• UPF-rated clothing for high-sun activities.
• Avoid peak sun hours (10 AM – 4 PM).
• Avoid tanning beds (Class 1 carcinogen).
• Be cautious of reflected UV (sand, water, snow).
• Window UV exposure also accumulates (UVA penetrates glass).

The Bottom Line

Skin cancer screening involves examination of skin for suspicious lesions — moles, growths, sores that might be cancerous. Two main approaches: self-exam (monthly self-check using mirror; check all areas including back, scalp, between toes, soles of feet, genitals; look for new lesions or changes using ABCDE criteria) and clinician skin exam (full-body inspection by dermatologist or primary care provider; dermatoscope used to evaluate suspicious lesions; biopsy any suspicious lesions). Skin cancers screened: basal cell carcinoma (most common — about 80% of skin cancers; rarely metastasizes; usually curable); squamous cell carcinoma (about 20%; can metastasize especially if neglected); melanoma (about 1% but most deadly; early detection critical); rarer types like Merkel cell carcinoma. USPSTF 2023 conclusion — insufficient evidence to recommend FOR or AGAINST routine screening in asymptomatic adults; risk-based approach commonly used. Adults with type 2 diabetes have modestly elevated risk: squamous cell carcinoma about 15-20% increased risk; basal cell carcinoma about 10% increased risk; melanoma possibly modest increased risk (less clear). Possible mechanisms: hyperinsulinemia and IGF-1 promoting tumor growth; chronic inflammation; immune dysfunction; oxidative stress. However, sun exposure remains by far the dominant skin cancer risk factor. Highest risk individuals: fair skin, history of sunburns, lots of moles, family history of melanoma, immunosuppression, prior skin cancer. Diabetes-associated skin conditions warrant monitoring: acanthosis nigricans (insulin resistance marker), diabetic dermopathy (shin spots — benign), necrobiosis lipoidica (uncommon; rarely transforms; monitor), diabetic bullae (spontaneous blisters), eruptive xanthomas (high triglycerides), skin tags (insulin resistance), diabetic ulcers (especially foot ulcers — serious; squamous cell carcinoma risk in chronic ulcers). ABCDE warning signs for moles: Asymmetry, Border irregular, Color uneven, Diameter greater than 6 mm, Evolving (changing). Additional Ugly Duckling sign — mole different from others. Non-melanoma warning signs: new sore that doesn’t heal in 4-6 weeks; persistent rough scaly patch; pearly bump or nodule; recurrent crust or bleeding lesion. Sun protection: SPF 30+ broad-spectrum daily; reapply every 2 hours; hat; sunglasses; long sleeves; avoid peak hours (10 AM – 4 PM); avoid tanning beds (Class 1 carcinogen). When to see dermatologist: any new mole after age 30; changing mole; lesion meeting ABCDE criteria; non-healing sore; concerning skin changes. For adults with diabetes — annual dermatologist visit reasonable for high-risk individuals; vigilant monitoring of diabetes-specific skin conditions; aggressive treatment of any chronic ulcer. See our broader prediabetes detection guide.

Lung cancer screening uses low-dose computed tomography (LDCT) — a CT scan with much lower radiation than diagnostic CT — to find lung cancers early in high-risk individuals. Procedure: lie on CT table; breath-hold; CT scanner takes images of chest; about 10-15 minutes total; no IV contrast typically; very low radiation (1-1.5 mSv vs 7 mSv standard chest CT). Detects: lung nodules (small spots); ground-glass opacities (early cancer); mediastinal abnormalities. Limitations: many false positives (most nodules are benign — granulomas, scars); incidental findings (other findings requiring evaluation); radiation exposure (cumulative over years); overdiagnosis (some cancers detected wouldn’t have caused harm). Strong evidence reduces lung cancer mortality 20-25% in eligible screened populations (National Lung Screening Trial and NELSON trial). USPSTF (2021 update — expanded eligibility): annual LDCT screening for adults meeting ALL criteria: age 50-80 (lowered from 55 in previous guidelines); 20+ pack-year smoking history (lowered from 30; pack-year = packs/day × years smoked; example: 1 pack/day for 20 years = 20 pack-years); currently smoking OR quit within past 15 years; in good enough health to benefit from early diagnosis and treatment (no severe comorbidity limiting life expectancy). Discontinue screening: once not smoked for 15 years, health problem limits ability to undergo curative lung surgery, or develops health condition shortening life. Diabetes alone doesn’t qualify for lung cancer screening. However, smoking and diabetes massively compound cardiovascular and cancer mortality — smoking cessation extremely important for adults with diabetes. About 8 million U.S. adults eligible under 2021 criteria but less than 20% actually screened. Synergistic harm — smoking and diabetes combination much worse than either alone. Cardiovascular disease — already main cause of death in diabetes; smoking dramatically increases CV mortality; adults with diabetes who smoke have 2-3x higher mortality than those who don’t smoke. Lung cancer — adults with diabetes who smoke have higher lung cancer risk than smokers without diabetes (modest 10-20% increase); diabetes also associated with worse lung cancer outcomes. Microvascular complications — smoking worsens diabetic retinopathy, nephropathy, neuropathy. Wound healing — smoking impairs all wound healing; combined with diabetic vascular changes especially problematic. Insulin resistance — smoking worsens insulin resistance; quitting improves insulin sensitivity. Peripheral artery disease — much more common in smokers with diabetes; major amputation risk. Quitting smoking is the single most important health intervention for adults with diabetes who smoke. Benefits begin within hours; mortality benefit accrues over years.

USPSTF Lung Cancer Screening Criteria (2021)

Pack-Year Calculation

Lung-RADS Findings Categories

• Lung-RADS 1 — negative; no nodules; continue annual screening.
• Lung-RADS 2 — benign findings; continue annual screening.
• Lung-RADS 3 — probably benign; follow-up CT in 6 months.
• Lung-RADS 4A — suspicious; follow-up CT in 3 months or PET scan.
• Lung-RADS 4B — more suspicious; PET scan, possible biopsy.
• Lung-RADS 4X — most suspicious (additional features); biopsy.
• Most nodules are Lung-RADS 1, 2, or 3.
• Most “abnormal” findings turn out to be benign.

Smoking Cessation for Adults with Diabetes

• Single most important health intervention for smokers with diabetes.
• Benefits begin within hours of quitting.
• CV mortality decreases substantially within 1-2 years.
• Insulin sensitivity improves.
• Microvascular complications progress slower.
• Lung cancer risk decreases over years.
• Available aids: nicotine replacement (patch, gum, lozenge), varenicline (Chantix), bupropion (Zyban), counseling.
• Combination therapy (medication + counseling) most effective.
• National quit line: 1-800-QUIT-NOW (free).
• Weight gain common after quitting but benefits far outweigh weight effect.
• Many attempts often needed — don’t give up if first attempt fails.

The Bottom Line

Lung cancer screening uses low-dose computed tomography (LDCT) — a CT scan with much lower radiation than diagnostic CT — to find lung cancers early in high-risk individuals. Procedure: lie on CT table; breath-hold; CT scanner takes images of chest; about 10-15 minutes total; no IV contrast typically; very low radiation (1-1.5 mSv vs 7 mSv standard chest CT). Detects: lung nodules (small spots); ground-glass opacities (early cancer); mediastinal abnormalities. Limitations: many false positives (most nodules are benign — granulomas, scars); incidental findings; radiation exposure; overdiagnosis. Strong evidence reduces lung cancer mortality 20-25% in eligible screened populations (National Lung Screening Trial and NELSON trial). USPSTF (2021 update — expanded eligibility): annual LDCT screening for adults meeting ALL criteria: age 50-80; 20+ pack-year smoking history (pack-year = packs/day × years smoked); currently smoking OR quit within past 15 years; in good enough health to benefit from early diagnosis and treatment. Discontinue screening: once not smoked for 15 years, health problem limits ability to undergo curative lung surgery, or develops health condition shortening life. About 8 million U.S. adults eligible under 2021 criteria but less than 20% actually screened. Diabetes alone doesn’t qualify for lung cancer screening — must meet smoking criteria. However, smoking and diabetes massively compound cardiovascular and cancer mortality — smoking cessation extremely important for adults with diabetes. Synergistic harm — combination much worse than either alone. Cardiovascular disease — already main cause of death in diabetes; smoking dramatically increases CV mortality; adults with diabetes who smoke have 2-3x higher mortality than those who don’t smoke. Lung cancer — adults with diabetes who smoke have higher lung cancer risk than smokers without diabetes (modest 10-20% increase); diabetes also associated with worse lung cancer outcomes. Microvascular complications — smoking worsens diabetic retinopathy, nephropathy, neuropathy. Wound healing — smoking impairs all wound healing; combined with diabetic vascular changes especially problematic. Insulin resistance — smoking worsens insulin resistance; quitting improves insulin sensitivity. Peripheral artery disease — much more common in smokers with diabetes; major amputation risk. Quitting smoking is the single most important health intervention for adults with diabetes who smoke. Benefits begin within hours; mortality benefit accrues over years. LDCT procedure: minimal preparation; about 10-15 minutes; results typically 1-3 days; Lung-RADS classification (1-4) categorizes findings; most results are Lung-RADS 1 or 2 (negative or benign findings) — continue annual screening; even suspicious lesions are not always cancer. For adults with diabetes who currently smoke or quit within 15 years and meet criteria — annual LDCT screening recommended. For adults with diabetes who smoke — quitting is most important step. Available aids: nicotine replacement, varenicline (Chantix), bupropion (Zyban), counseling, national quit line 1-800-QUIT-NOW. See our broader prediabetes detection guide.

Prostate screening consists of two main tests. PSA (prostate-specific antigen) — blood test measuring protein produced by prostate cells; elevated levels may indicate cancer or other conditions (BPH, prostatitis); most widely used screening test; normal generally under 4 ng/mL but age-adjusted ranges used. DRE (digital rectal exam) — provider inserts gloved lubricated finger into rectum to feel prostate gland; checks for size, shape, abnormalities (hard nodules, asymmetry); brief procedure (less than 1 minute); some discomfort but minimal pain. Modern approach: PSA primary screening tool; DRE often added; both have limitations. PSA limitations: many false positives (BPH, prostatitis cause elevated PSA); doesn’t identify aggressive vs indolent cancers; overdiagnosis concerns. Newer tools: PSA velocity, PSA density, free PSA ratio, MRI, biomarker tests (4Kscore, PHI) help refine risk after elevated PSA. USPSTF guidelines (2018): age 55-69 — shared decision-making about PSA screening (modest benefit — 1 prostate cancer death prevented per 1000 men screened over 13 years; modest harms — false positives, biopsy complications, overdiagnosis, treatment side effects like incontinence, ED); age 70+ — recommend against routine PSA screening. Earlier screening for higher risk: African American men (start age 45-50; higher prostate cancer incidence and mortality); family history (start 40-45 if first-degree relative with prostate cancer); BRCA1/BRCA2 mutations or Lynch syndrome (start age 40 with annual screening). American Urological Association similar. Diabetes alone doesn’t change recommendations but discuss diabetes-specific issues with provider. Diabetes complicates prostate cancer picture with paradoxical findings. Lower PSA levels — men with type 2 diabetes have about 10-15% lower PSA than men without diabetes (mechanism: lower testosterone in diabetes, smaller prostate size, possible direct effects); this may MASK cancer (cancer present but PSA below threshold for biopsy). Lower prostate cancer INCIDENCE in men with diabetes (about 10-15% reduced risk in long-standing diabetes — opposite of most other cancers); but higher prostate cancer MORTALITY in diabetes (about 30% increased mortality if cancer diagnosed). More aggressive disease at diagnosis — possibly because lower PSA delays diagnosis. Worse outcomes after treatment due to comorbidities. Interpretation: standard PSA thresholds may miss cancer in diabetes; some experts suggest lower thresholds (3.0 ng/mL instead of 4.0). Discuss with provider. Diabetes management, comorbidity control important for outcomes.

USPSTF Guidelines (2018)

Diabetes Effects on Prostate Cancer

Causes of Elevated PSA

• Prostate cancer (most concerning, but not most common cause).
• BPH (benign prostatic hyperplasia — enlarged prostate) — very common.
• Prostatitis (inflammation/infection of prostate).
• Recent ejaculation (within 24-48 hours).
• Recent vigorous exercise (especially cycling).
• Recent urinary tract instrumentation (catheter, cystoscopy).
• Recent prostate biopsy or DRE (test on different day).
• Aging (PSA increases with age in general).
• Race (African American men have slightly higher PSA naturally).

Follow-up After Elevated PSA

• Repeat PSA in 4-6 weeks (rule out transient elevation).
• Check free PSA ratio (lower ratio more concerning).
• Prostate MRI (multiparametric) — increasingly used before biopsy.
• If MRI suspicious — MRI-guided biopsy.
• If MRI not suspicious — may avoid biopsy or do systematic biopsy.
• Biomarker tests (4Kscore, PHI, ExoDx, SelectMDx) — refine risk before biopsy.
• If biopsy positive — treatment decisions: active surveillance, surgery, radiation, hormone therapy.
• Active surveillance reasonable for low-risk cancer in older men.

The Bottom Line

Prostate screening consists of two main tests. PSA (prostate-specific antigen) — blood test measuring protein produced by prostate cells; elevated levels may indicate cancer or other conditions (BPH, prostatitis); most widely used screening test; normal generally under 4 ng/mL but age-adjusted ranges used. DRE (digital rectal exam) — provider inserts gloved lubricated finger into rectum to feel prostate gland; checks for size, shape, abnormalities (hard nodules, asymmetry); brief procedure; some discomfort but minimal pain. Modern approach: PSA primary screening tool; DRE often added; both have limitations. PSA limitations: many false positives (BPH, prostatitis cause elevated PSA); doesn’t identify aggressive vs indolent cancers; overdiagnosis concerns. Newer tools: PSA velocity, PSA density, free PSA ratio, MRI, biomarker tests (4Kscore, PHI) help refine risk after elevated PSA. USPSTF guidelines (2018): age 55-69 — shared decision-making about PSA screening (modest benefit — 1 prostate cancer death prevented per 1000 men screened over 13 years; modest harms — false positives, biopsy complications, overdiagnosis, treatment side effects like incontinence, ED); age 70+ — recommend against routine PSA screening. Earlier screening for higher risk: African American men (start age 45-50), family history (start 40-45 if first-degree relative), BRCA1/BRCA2 mutations or Lynch syndrome (start age 40). American Urological Association similar. Diabetes complicates prostate cancer picture with paradoxical findings. Lower PSA levels — men with type 2 diabetes have about 10-15% lower PSA than men without diabetes (mechanism: lower testosterone in diabetes, smaller prostate size, possible direct effects); this may MASK cancer. Lower prostate cancer INCIDENCE in men with diabetes (about 10-15% reduced risk in long-standing diabetes — opposite of most other cancers); but higher prostate cancer MORTALITY in diabetes (about 30% increased mortality if cancer diagnosed). More aggressive disease at diagnosis — possibly because lower PSA delays diagnosis. Worse outcomes after treatment due to comorbidities. Interpretation: standard PSA thresholds may miss cancer in diabetes; some experts suggest lower thresholds. Discuss with provider. Procedure: PSA blood test is simple draw; DRE — undress from waist down; lean forward over exam table or bend at waist or lie on left side with knees pulled up; provider explains procedure; lubricated gloved finger inserted into rectum; prostate felt for 20-30 seconds; finger withdrawn; brief discomfort and possible pressure-to-urinate sensation; minimal pain for most men. Results: DRE findings discussed immediately; PSA in 1-3 days. If PSA elevated: repeat PSA in few weeks, check free PSA ratio, possible prostate MRI, then biopsy if suspicious. Most elevated PSA results are NOT prostate cancer — BPH (enlarged prostate) most common cause; prostatitis; recent ejaculation or vigorous exercise. For men with diabetes — discuss prostate screening with provider with diabetes-specific considerations in mind. See our broader prediabetes detection guide.